Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Durez

Showing results (81-90 of 118) with videos related to

Pageof 12
Sort By:
Annals of the Rheumatic Diseases|July 28, 2023
Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitisClément Triaille, Gaëlle Tilman, Tatiana Sokolova, et al.
The Journal of Rheumatology|January 17, 2014
One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled studyMark C Genovese, Patrick Durez, Hanno B Richards, et al.
Annals of the Rheumatic Diseases|June 26, 2012
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled studyMark C Genovese, Patrick Durez, Hanno B Richards, et al.
RMD Open|June 24, 2026
Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE studyRoy Fleischmann, Jerzy Swierkot, Patrick Durez, et al.
Annals of the Rheumatic Diseases|January 1, 2015
Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosisRene Westhovens, Manuel Robles, Antonio Carlos Ximenes, et al.
Lancet (London, England)|January 22, 2013
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trialJosef S Smolen, Peter Nash, Patrick Durez, et al.
Arthritis Care & Research|July 18, 2013
Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled studyPaul Emery, Roy M Fleischmann, Mittie K Doyle, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 23, 2024
Two Broad Categories Overlapping With Rheumatoid Arthritis Observed in Synovial Biopsies from Patients With Juvenile Idiopathic ArthritisClément Triaille, Gaëlle Tilman, Charlotte A Baert, et al.
Arthritis Research & Therapy|September 19, 2006
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activityBert Vander Cruyssen, Stijn Van Looy, Bart Wyns, et al.
The Journal of Rheumatology|March 4, 2014
Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trialMark C Genovese, César Pacheco Tena, Arturo Covarrubias, et al.
Pageof 12

Showing results (81-90 of 118) with videos related to

Sort By:
Pageof 12
Annals of the Rheumatic Diseases|July 28, 2023
Disease activity drives transcriptomic heterogeneity in early untreated rheumatoid synovitisClément Triaille, Gaëlle Tilman, Tatiana Sokolova, et al.
The Journal of Rheumatology|January 17, 2014
One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled studyMark C Genovese, Patrick Durez, Hanno B Richards, et al.
Annals of the Rheumatic Diseases|June 26, 2012
Efficacy and safety of secukinumab in patients with rheumatoid arthritis: a phase II, dose-finding, double-blind, randomised, placebo controlled studyMark C Genovese, Patrick Durez, Hanno B Richards, et al.
RMD Open|June 24, 2026
Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE studyRoy Fleischmann, Jerzy Swierkot, Patrick Durez, et al.
Annals of the Rheumatic Diseases|January 1, 2015
Maintenance of remission following 2 years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosisRene Westhovens, Manuel Robles, Antonio Carlos Ximenes, et al.
Lancet (London, England)|January 22, 2013
Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trialJosef S Smolen, Peter Nash, Patrick Durez, et al.
Arthritis Care & Research|July 18, 2013
Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled studyPaul Emery, Roy M Fleischmann, Mittie K Doyle, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|May 23, 2024
Two Broad Categories Overlapping With Rheumatoid Arthritis Observed in Synovial Biopsies from Patients With Juvenile Idiopathic ArthritisClément Triaille, Gaëlle Tilman, Charlotte A Baert, et al.
Arthritis Research & Therapy|September 19, 2006
Four-year follow-up of infliximab therapy in rheumatoid arthritis patients with long-standing refractory disease: attrition and long-term evolution of disease activityBert Vander Cruyssen, Stijn Van Looy, Bart Wyns, et al.
The Journal of Rheumatology|March 4, 2014
Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trialMark C Genovese, César Pacheco Tena, Arturo Covarrubias, et al.
Pageof 12